Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy

被引:25
作者
Chen, B
Timiryasova, TM
Gridley, DS
Andres, ML
Dutta-Roy, R
Fodor, I
机构
[1] Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA
[2] Loma Linda Univ, Sch Med, Dept Microbiol & Mol Genet, Loma Linda, CA 92350 USA
[3] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92350 USA
关键词
glioma; IL-2; IL-12; toxicity; vaccinia virus;
D O I
10.1006/cyto.2001.0906
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Single intratumoural treatment of nude mice with a vaccinia virus (VV)-expressing interleukin-1 (IL-2) or IL-12 induced significant tumour growth inhibition associated with clear signs of toxicity. At a low virus dose, only some treated animals showed signs of toxicity. We characterized and compared the activity of NK and B cells and major pro-inflammatory factors (IFN-gamma, TNF-alpha) in treated animals with and without toxicity. One week after treatment animals exhibiting signs of cytokine-related toxicity showed dramatic increases in several measured parameters. High leukocyte and lymphocyte counts in blood and marked increases in NK and CD25(+) cells in both blood and spleen were associated with IL-2-induced toxicity, while IL-12-induced toxicity was related to a great elevation of CD25(+) cells in blood and CD71(+) cells in the spleen. In contrast, immune activation in animals free of toxicity was observed on day 2 after the treatment, which drastically declined by day 7. Thus, immune responses induced by IL-2 and IL-12 therapy appear to play important roles in both tumour inhibition and the accompanying toxicity. Short-term effects induced by IL-2 and IL-12 could be critical for antitumour therapy that prolongs survival and protects from adverse side effects.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 39 条
[1]   Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors [J].
Addison, CL ;
Bramson, JL ;
Hitt, MM ;
Muller, WJ ;
Gauldie, J ;
Graham, FL .
GENE THERAPY, 1998, 5 (10) :1400-1409
[2]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[3]  
BLOM U, 1985, ANTICANCER RES, V5, P343
[4]  
BOCCOLI G, 1990, CANCER RES, V50, P5795
[5]   Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 [J].
Bramson, JL ;
Hitt, M ;
Addison, CL ;
Muller, WJ ;
Gauldie, J ;
Graham, FL .
HUMAN GENE THERAPY, 1996, 7 (16) :1995-2002
[6]   In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2 [J].
Bui, LA ;
Butterfield, LH ;
Kim, JY ;
Ribas, A ;
Seu, P ;
Lau, R ;
Glaspy, JA ;
McBride, WH ;
Economou, JS .
HUMAN GENE THERAPY, 1997, 8 (18) :2173-2182
[7]  
Carson WE, 1999, J IMMUNOL, V162, P4943
[8]   Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model [J].
Chen, B ;
Timiryasova, TM ;
Andres, ML ;
Kajioka, EH ;
Dutta-Roy, R ;
Gridley, DS ;
Fodor, I .
CANCER GENE THERAPY, 2000, 7 (11) :1437-1447
[9]   Low-dose vaccinia virus-mediated cytokine gene therapy of glioma [J].
Chen, B ;
Timiryasova, TM ;
Haghighat, P ;
Andres, ML ;
Kajioka, EH ;
Dutta-Roy, R ;
Gridley, DS ;
Fodor, I .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (01) :46-57
[10]  
Chen L, 1997, J IMMUNOL, V159, P351